nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—CYP3A4—Estropipate—osteoporosis	0.0369	0.181	CbGbCtD
Orlistat—CYP3A4—Calcitriol—osteoporosis	0.0369	0.181	CbGbCtD
Orlistat—CYP3A4—Ergocalciferol—osteoporosis	0.0295	0.145	CbGbCtD
Orlistat—CYP3A4—Raloxifene—osteoporosis	0.0247	0.121	CbGbCtD
Orlistat—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0238	0.117	CbGbCtD
Orlistat—CYP3A4—Cholecalciferol—osteoporosis	0.019	0.0934	CbGbCtD
Orlistat—CYP3A4—Conjugated Estrogens—osteoporosis	0.0175	0.0858	CbGbCtD
Orlistat—CYP3A4—Estradiol—osteoporosis	0.0153	0.0753	CbGbCtD
Orlistat—PLA2G4A—Estradiol—Estropipate—osteoporosis	0.0025	0.417	CbGdCrCtD
Orlistat—PLA2G4A—Estradiol—Conjugated Estrogens—osteoporosis	0.00189	0.316	CbGdCrCtD
Orlistat—PLA2G4A—Estradiol—Ethinyl Estradiol—osteoporosis	0.00159	0.266	CbGdCrCtD
Orlistat—Oedema—Pamidronate—osteoporosis	0.000341	0.000781	CcSEcCtD
Orlistat—Haemoglobin—Estradiol—osteoporosis	0.00034	0.000777	CcSEcCtD
Orlistat—Infection—Pamidronate—osteoporosis	0.000339	0.000776	CcSEcCtD
Orlistat—Urticaria—Calcitriol—osteoporosis	0.000339	0.000775	CcSEcCtD
Orlistat—Haemorrhage—Estradiol—osteoporosis	0.000338	0.000774	CcSEcCtD
Orlistat—Hepatitis—Estradiol—osteoporosis	0.000338	0.000774	CcSEcCtD
Orlistat—Palpitations—Zoledronate—osteoporosis	0.000337	0.000772	CcSEcCtD
Orlistat—Abdominal pain—Calcitriol—osteoporosis	0.000337	0.000771	CcSEcCtD
Orlistat—Body temperature increased—Calcitriol—osteoporosis	0.000337	0.000771	CcSEcCtD
Orlistat—Angioedema—Conjugated Estrogens—osteoporosis	0.000336	0.000769	CcSEcCtD
Orlistat—Pharyngitis—Estradiol—osteoporosis	0.000335	0.000768	CcSEcCtD
Orlistat—Hypersensitivity—Estropipate—osteoporosis	0.000334	0.000766	CcSEcCtD
Orlistat—Nervous system disorder—Pamidronate—osteoporosis	0.000334	0.000766	CcSEcCtD
Orlistat—Urinary tract disorder—Estradiol—osteoporosis	0.000334	0.000764	CcSEcCtD
Orlistat—Vomiting—Etidronic acid—osteoporosis	0.000334	0.000764	CcSEcCtD
Orlistat—Cough—Zoledronate—osteoporosis	0.000333	0.000762	CcSEcCtD
Orlistat—Oedema peripheral—Estradiol—osteoporosis	0.000333	0.000762	CcSEcCtD
Orlistat—Urethral disorder—Estradiol—osteoporosis	0.000331	0.000758	CcSEcCtD
Orlistat—Rash—Etidronic acid—osteoporosis	0.000331	0.000757	CcSEcCtD
Orlistat—Convulsion—Zoledronate—osteoporosis	0.000331	0.000757	CcSEcCtD
Orlistat—Dermatitis—Etidronic acid—osteoporosis	0.000331	0.000757	CcSEcCtD
Orlistat—Vertigo—Conjugated Estrogens—osteoporosis	0.00033	0.000756	CcSEcCtD
Orlistat—Hyperhidrosis—Pamidronate—osteoporosis	0.00033	0.000755	CcSEcCtD
Orlistat—Hypersensitivity—Alendronate—osteoporosis	0.000329	0.000754	CcSEcCtD
Orlistat—Headache—Etidronic acid—osteoporosis	0.000329	0.000752	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000327	0.000748	CcSEcCtD
Orlistat—Asthenia—Estropipate—osteoporosis	0.000326	0.000746	CcSEcCtD
Orlistat—Myalgia—Zoledronate—osteoporosis	0.000325	0.000744	CcSEcCtD
Orlistat—Chest pain—Zoledronate—osteoporosis	0.000325	0.000744	CcSEcCtD
Orlistat—Palpitations—Conjugated Estrogens—osteoporosis	0.000325	0.000743	CcSEcCtD
Orlistat—Insomnia—Risedronate—osteoporosis	0.000324	0.000743	CcSEcCtD
Orlistat—Anxiety—Zoledronate—osteoporosis	0.000324	0.000741	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000323	0.000739	CcSEcCtD
Orlistat—Paraesthesia—Risedronate—osteoporosis	0.000322	0.000737	CcSEcCtD
Orlistat—Pruritus—Estropipate—osteoporosis	0.000321	0.000735	CcSEcCtD
Orlistat—Discomfort—Zoledronate—osteoporosis	0.000321	0.000735	CcSEcCtD
Orlistat—Asthenia—Alendronate—osteoporosis	0.000321	0.000734	CcSEcCtD
Orlistat—Hypersensitivity—Ibandronate—osteoporosis	0.000321	0.000734	CcSEcCtD
Orlistat—Cough—Conjugated Estrogens—osteoporosis	0.000321	0.000734	CcSEcCtD
Orlistat—Convulsion—Conjugated Estrogens—osteoporosis	0.000318	0.000729	CcSEcCtD
Orlistat—Dry mouth—Zoledronate—osteoporosis	0.000318	0.000728	CcSEcCtD
Orlistat—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000318	0.000727	CcSEcCtD
Orlistat—Fatigue—Ethinyl Estradiol—osteoporosis	0.000317	0.000726	CcSEcCtD
Orlistat—Pruritus—Alendronate—osteoporosis	0.000316	0.000724	CcSEcCtD
Orlistat—Dyspepsia—Risedronate—osteoporosis	0.000316	0.000723	CcSEcCtD
Orlistat—Hypersensitivity—Calcitriol—osteoporosis	0.000314	0.000719	CcSEcCtD
Orlistat—Chest pain—Conjugated Estrogens—osteoporosis	0.000313	0.000716	CcSEcCtD
Orlistat—Myalgia—Conjugated Estrogens—osteoporosis	0.000313	0.000716	CcSEcCtD
Orlistat—Asthenia—Ibandronate—osteoporosis	0.000312	0.000715	CcSEcCtD
Orlistat—Anxiety—Conjugated Estrogens—osteoporosis	0.000312	0.000714	CcSEcCtD
Orlistat—Nausea—Etidronic acid—osteoporosis	0.000312	0.000713	CcSEcCtD
Orlistat—Anaphylactic shock—Zoledronate—osteoporosis	0.000311	0.000713	CcSEcCtD
Orlistat—Oedema—Zoledronate—osteoporosis	0.000311	0.000713	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000311	0.000711	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000311	0.000711	CcSEcCtD
Orlistat—Diarrhoea—Estropipate—osteoporosis	0.000311	0.000711	CcSEcCtD
Orlistat—Gastrointestinal disorder—Risedronate—osteoporosis	0.00031	0.000709	CcSEcCtD
Orlistat—Infection—Zoledronate—osteoporosis	0.000309	0.000708	CcSEcCtD
Orlistat—Fatigue—Risedronate—osteoporosis	0.000309	0.000708	CcSEcCtD
Orlistat—Insomnia—Pamidronate—osteoporosis	0.000308	0.000706	CcSEcCtD
Orlistat—Pruritus—Ibandronate—osteoporosis	0.000308	0.000705	CcSEcCtD
Orlistat—Pain—Risedronate—osteoporosis	0.000307	0.000702	CcSEcCtD
Orlistat—Paraesthesia—Pamidronate—osteoporosis	0.000306	0.000701	CcSEcCtD
Orlistat—Diarrhoea—Alendronate—osteoporosis	0.000306	0.0007	CcSEcCtD
Orlistat—Asthenia—Calcitriol—osteoporosis	0.000306	0.0007	CcSEcCtD
Orlistat—Nervous system disorder—Zoledronate—osteoporosis	0.000305	0.000699	CcSEcCtD
Orlistat—Immune system disorder—Estradiol—osteoporosis	0.000305	0.000699	CcSEcCtD
Orlistat—Mediastinal disorder—Estradiol—osteoporosis	0.000305	0.000697	CcSEcCtD
Orlistat—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000303	0.000694	CcSEcCtD
Orlistat—Skin disorder—Zoledronate—osteoporosis	0.000303	0.000693	CcSEcCtD
Orlistat—Pruritus—Calcitriol—osteoporosis	0.000301	0.00069	CcSEcCtD
Orlistat—Hyperhidrosis—Zoledronate—osteoporosis	0.000301	0.000689	CcSEcCtD
Orlistat—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000301	0.000689	CcSEcCtD
Orlistat—Diarrhoea—Raloxifene—osteoporosis	0.000301	0.000689	CcSEcCtD
Orlistat—Dyspepsia—Pamidronate—osteoporosis	0.0003	0.000687	CcSEcCtD
Orlistat—Dizziness—Estropipate—osteoporosis	0.0003	0.000687	CcSEcCtD
Orlistat—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.0003	0.000687	CcSEcCtD
Orlistat—Oedema—Conjugated Estrogens—osteoporosis	0.0003	0.000687	CcSEcCtD
Orlistat—Alopecia—Estradiol—osteoporosis	0.000299	0.000684	CcSEcCtD
Orlistat—Infection—Conjugated Estrogens—osteoporosis	0.000298	0.000682	CcSEcCtD
Orlistat—Diarrhoea—Ibandronate—osteoporosis	0.000298	0.000682	CcSEcCtD
Orlistat—Decreased appetite—Pamidronate—osteoporosis	0.000296	0.000679	CcSEcCtD
Orlistat—Mental disorder—Estradiol—osteoporosis	0.000296	0.000678	CcSEcCtD
Orlistat—Dizziness—Alendronate—osteoporosis	0.000296	0.000677	CcSEcCtD
Orlistat—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000294	0.000674	CcSEcCtD
Orlistat—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000294	0.000673	CcSEcCtD
Orlistat—Malnutrition—Estradiol—osteoporosis	0.000294	0.000673	CcSEcCtD
Orlistat—Fatigue—Pamidronate—osteoporosis	0.000294	0.000673	CcSEcCtD
Orlistat—Gastrointestinal pain—Risedronate—osteoporosis	0.000293	0.000672	CcSEcCtD
Orlistat—Urticaria—Ethinyl Estradiol—osteoporosis	0.000292	0.000669	CcSEcCtD
Orlistat—Pain—Pamidronate—osteoporosis	0.000292	0.000668	CcSEcCtD
Orlistat—Diarrhoea—Calcitriol—osteoporosis	0.000292	0.000667	CcSEcCtD
Orlistat—Skin disorder—Conjugated Estrogens—osteoporosis	0.000291	0.000667	CcSEcCtD
Orlistat—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000291	0.000666	CcSEcCtD
Orlistat—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000291	0.000666	CcSEcCtD
Orlistat—Dizziness—Raloxifene—osteoporosis	0.000291	0.000666	CcSEcCtD
Orlistat—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.00029	0.000664	CcSEcCtD
Orlistat—Flatulence—Estradiol—osteoporosis	0.00029	0.000664	CcSEcCtD
Orlistat—Vomiting—Estropipate—osteoporosis	0.000289	0.000661	CcSEcCtD
Orlistat—Dysgeusia—Estradiol—osteoporosis	0.000288	0.000659	CcSEcCtD
Orlistat—Dizziness—Ibandronate—osteoporosis	0.000288	0.000659	CcSEcCtD
Orlistat—Rash—Estropipate—osteoporosis	0.000286	0.000655	CcSEcCtD
Orlistat—Dermatitis—Estropipate—osteoporosis	0.000286	0.000655	CcSEcCtD
Orlistat—Urticaria—Risedronate—osteoporosis	0.000285	0.000652	CcSEcCtD
Orlistat—Back pain—Estradiol—osteoporosis	0.000285	0.000651	CcSEcCtD
Orlistat—Headache—Estropipate—osteoporosis	0.000284	0.000651	CcSEcCtD
Orlistat—Vomiting—Alendronate—osteoporosis	0.000284	0.000651	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000284	0.00065	CcSEcCtD
Orlistat—Abdominal pain—Risedronate—osteoporosis	0.000284	0.000649	CcSEcCtD
Orlistat—Body temperature increased—Risedronate—osteoporosis	0.000284	0.000649	CcSEcCtD
Orlistat—Muscle spasms—Estradiol—osteoporosis	0.000283	0.000647	CcSEcCtD
Orlistat—Rash—Alendronate—osteoporosis	0.000282	0.000645	CcSEcCtD
Orlistat—Insomnia—Zoledronate—osteoporosis	0.000282	0.000645	CcSEcCtD
Orlistat—Dermatitis—Alendronate—osteoporosis	0.000282	0.000645	CcSEcCtD
Orlistat—Feeling abnormal—Pamidronate—osteoporosis	0.000281	0.000643	CcSEcCtD
Orlistat—Headache—Alendronate—osteoporosis	0.00028	0.000641	CcSEcCtD
Orlistat—Paraesthesia—Zoledronate—osteoporosis	0.00028	0.00064	CcSEcCtD
Orlistat—Vomiting—Raloxifene—osteoporosis	0.00028	0.00064	CcSEcCtD
Orlistat—Gastrointestinal pain—Pamidronate—osteoporosis	0.000279	0.000638	CcSEcCtD
Orlistat—Rash—Raloxifene—osteoporosis	0.000277	0.000635	CcSEcCtD
Orlistat—Dermatitis—Raloxifene—osteoporosis	0.000277	0.000634	CcSEcCtD
Orlistat—Vomiting—Ibandronate—osteoporosis	0.000277	0.000634	CcSEcCtD
Orlistat—Headache—Raloxifene—osteoporosis	0.000275	0.000631	CcSEcCtD
Orlistat—Rash—Ibandronate—osteoporosis	0.000274	0.000628	CcSEcCtD
Orlistat—Dermatitis—Ibandronate—osteoporosis	0.000274	0.000628	CcSEcCtD
Orlistat—Dyspepsia—Zoledronate—osteoporosis	0.000274	0.000628	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000273	0.000626	CcSEcCtD
Orlistat—Ill-defined disorder—Estradiol—osteoporosis	0.000273	0.000625	CcSEcCtD
Orlistat—Headache—Ibandronate—osteoporosis	0.000273	0.000624	CcSEcCtD
Orlistat—Insomnia—Conjugated Estrogens—osteoporosis	0.000271	0.000621	CcSEcCtD
Orlistat—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000271	0.000621	CcSEcCtD
Orlistat—Vomiting—Calcitriol—osteoporosis	0.000271	0.00062	CcSEcCtD
Orlistat—Decreased appetite—Zoledronate—osteoporosis	0.000271	0.00062	CcSEcCtD
Orlistat—Nausea—Estropipate—osteoporosis	0.00027	0.000617	CcSEcCtD
Orlistat—Abdominal pain—Pamidronate—osteoporosis	0.00027	0.000617	CcSEcCtD
Orlistat—Body temperature increased—Pamidronate—osteoporosis	0.00027	0.000617	CcSEcCtD
Orlistat—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000269	0.000617	CcSEcCtD
Orlistat—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000269	0.000616	CcSEcCtD
Orlistat—Angioedema—Estradiol—osteoporosis	0.000269	0.000615	CcSEcCtD
Orlistat—Rash—Calcitriol—osteoporosis	0.000269	0.000615	CcSEcCtD
Orlistat—Fatigue—Zoledronate—osteoporosis	0.000269	0.000615	CcSEcCtD
Orlistat—Dermatitis—Calcitriol—osteoporosis	0.000268	0.000614	CcSEcCtD
Orlistat—Headache—Calcitriol—osteoporosis	0.000267	0.000611	CcSEcCtD
Orlistat—Pain—Zoledronate—osteoporosis	0.000266	0.00061	CcSEcCtD
Orlistat—Nausea—Alendronate—osteoporosis	0.000266	0.000608	CcSEcCtD
Orlistat—Malaise—Estradiol—osteoporosis	0.000265	0.000607	CcSEcCtD
Orlistat—Hypersensitivity—Risedronate—osteoporosis	0.000264	0.000605	CcSEcCtD
Orlistat—Vertigo—Estradiol—osteoporosis	0.000264	0.000605	CcSEcCtD
Orlistat—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000264	0.000604	CcSEcCtD
Orlistat—Asthenia—Ethinyl Estradiol—osteoporosis	0.000264	0.000604	CcSEcCtD
Orlistat—Nausea—Raloxifene—osteoporosis	0.000261	0.000598	CcSEcCtD
Orlistat—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000261	0.000597	CcSEcCtD
Orlistat—Pruritus—Ethinyl Estradiol—osteoporosis	0.00026	0.000596	CcSEcCtD
Orlistat—Palpitations—Estradiol—osteoporosis	0.00026	0.000595	CcSEcCtD
Orlistat—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000259	0.000593	CcSEcCtD
Orlistat—Fatigue—Conjugated Estrogens—osteoporosis	0.000259	0.000592	CcSEcCtD
Orlistat—Nausea—Ibandronate—osteoporosis	0.000259	0.000592	CcSEcCtD
Orlistat—Asthenia—Risedronate—osteoporosis	0.000257	0.000589	CcSEcCtD
Orlistat—Feeling abnormal—Zoledronate—osteoporosis	0.000257	0.000588	CcSEcCtD
Orlistat—Cough—Estradiol—osteoporosis	0.000257	0.000588	CcSEcCtD
Orlistat—Pain—Conjugated Estrogens—osteoporosis	0.000256	0.000587	CcSEcCtD
Orlistat—Gastrointestinal pain—Zoledronate—osteoporosis	0.000255	0.000583	CcSEcCtD
Orlistat—Pruritus—Risedronate—osteoporosis	0.000254	0.000581	CcSEcCtD
Orlistat—Nausea—Calcitriol—osteoporosis	0.000253	0.000579	CcSEcCtD
Orlistat—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000252	0.000576	CcSEcCtD
Orlistat—Hypersensitivity—Pamidronate—osteoporosis	0.000251	0.000575	CcSEcCtD
Orlistat—Myalgia—Estradiol—osteoporosis	0.00025	0.000573	CcSEcCtD
Orlistat—Chest pain—Estradiol—osteoporosis	0.00025	0.000573	CcSEcCtD
Orlistat—Anxiety—Estradiol—osteoporosis	0.00025	0.000571	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000249	0.000569	CcSEcCtD
Orlistat—Urticaria—Zoledronate—osteoporosis	0.000247	0.000566	CcSEcCtD
Orlistat—Discomfort—Estradiol—osteoporosis	0.000247	0.000566	CcSEcCtD
Orlistat—Abdominal pain—Zoledronate—osteoporosis	0.000246	0.000564	CcSEcCtD
Orlistat—Body temperature increased—Zoledronate—osteoporosis	0.000246	0.000564	CcSEcCtD
Orlistat—Diarrhoea—Risedronate—osteoporosis	0.000245	0.000562	CcSEcCtD
Orlistat—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000245	0.000561	CcSEcCtD
Orlistat—Dry mouth—Estradiol—osteoporosis	0.000245	0.000561	CcSEcCtD
Orlistat—Asthenia—Pamidronate—osteoporosis	0.000245	0.00056	CcSEcCtD
Orlistat—Dizziness—Ethinyl Estradiol—osteoporosis	0.000243	0.000557	CcSEcCtD
Orlistat—Pruritus—Pamidronate—osteoporosis	0.000241	0.000552	CcSEcCtD
Orlistat—Oedema—Estradiol—osteoporosis	0.00024	0.00055	CcSEcCtD
Orlistat—Anaphylactic shock—Estradiol—osteoporosis	0.00024	0.00055	CcSEcCtD
Orlistat—Infection—Estradiol—osteoporosis	0.000238	0.000546	CcSEcCtD
Orlistat—Urticaria—Conjugated Estrogens—osteoporosis	0.000238	0.000545	CcSEcCtD
Orlistat—Dizziness—Risedronate—osteoporosis	0.000237	0.000543	CcSEcCtD
Orlistat—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000237	0.000543	CcSEcCtD
Orlistat—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000237	0.000543	CcSEcCtD
Orlistat—Nervous system disorder—Estradiol—osteoporosis	0.000235	0.000539	CcSEcCtD
Orlistat—Vomiting—Ethinyl Estradiol—osteoporosis	0.000234	0.000536	CcSEcCtD
Orlistat—Diarrhoea—Pamidronate—osteoporosis	0.000233	0.000534	CcSEcCtD
Orlistat—Skin disorder—Estradiol—osteoporosis	0.000233	0.000534	CcSEcCtD
Orlistat—Hyperhidrosis—Estradiol—osteoporosis	0.000232	0.000531	CcSEcCtD
Orlistat—Rash—Ethinyl Estradiol—osteoporosis	0.000232	0.000531	CcSEcCtD
Orlistat—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000232	0.000531	CcSEcCtD
Orlistat—Headache—Ethinyl Estradiol—osteoporosis	0.00023	0.000528	CcSEcCtD
Orlistat—Hypersensitivity—Zoledronate—osteoporosis	0.000229	0.000525	CcSEcCtD
Orlistat—Vomiting—Risedronate—osteoporosis	0.000228	0.000522	CcSEcCtD
Orlistat—Rash—Risedronate—osteoporosis	0.000226	0.000518	CcSEcCtD
Orlistat—Dermatitis—Risedronate—osteoporosis	0.000226	0.000517	CcSEcCtD
Orlistat—Dizziness—Pamidronate—osteoporosis	0.000226	0.000516	CcSEcCtD
Orlistat—Headache—Risedronate—osteoporosis	0.000225	0.000514	CcSEcCtD
Orlistat—Asthenia—Zoledronate—osteoporosis	0.000223	0.000512	CcSEcCtD
Orlistat—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000221	0.000506	CcSEcCtD
Orlistat—Pruritus—Zoledronate—osteoporosis	0.00022	0.000505	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000219	0.000501	CcSEcCtD
Orlistat—Nausea—Ethinyl Estradiol—osteoporosis	0.000219	0.0005	CcSEcCtD
Orlistat—Insomnia—Estradiol—osteoporosis	0.000217	0.000497	CcSEcCtD
Orlistat—Vomiting—Pamidronate—osteoporosis	0.000217	0.000496	CcSEcCtD
Orlistat—Paraesthesia—Estradiol—osteoporosis	0.000216	0.000493	CcSEcCtD
Orlistat—Asthenia—Conjugated Estrogens—osteoporosis	0.000215	0.000493	CcSEcCtD
Orlistat—Rash—Pamidronate—osteoporosis	0.000215	0.000492	CcSEcCtD
Orlistat—Dermatitis—Pamidronate—osteoporosis	0.000215	0.000492	CcSEcCtD
Orlistat—Headache—Pamidronate—osteoporosis	0.000214	0.000489	CcSEcCtD
Orlistat—Diarrhoea—Zoledronate—osteoporosis	0.000213	0.000488	CcSEcCtD
Orlistat—Nausea—Risedronate—osteoporosis	0.000213	0.000488	CcSEcCtD
Orlistat—Pruritus—Conjugated Estrogens—osteoporosis	0.000212	0.000486	CcSEcCtD
Orlistat—Dyspepsia—Estradiol—osteoporosis	0.000211	0.000484	CcSEcCtD
Orlistat—Decreased appetite—Estradiol—osteoporosis	0.000209	0.000478	CcSEcCtD
Orlistat—Gastrointestinal disorder—Estradiol—osteoporosis	0.000207	0.000474	CcSEcCtD
Orlistat—Fatigue—Estradiol—osteoporosis	0.000207	0.000474	CcSEcCtD
Orlistat—Dizziness—Zoledronate—osteoporosis	0.000206	0.000472	CcSEcCtD
Orlistat—Pain—Estradiol—osteoporosis	0.000205	0.00047	CcSEcCtD
Orlistat—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000205	0.00047	CcSEcCtD
Orlistat—Nausea—Pamidronate—osteoporosis	0.000203	0.000464	CcSEcCtD
Orlistat—Dizziness—Conjugated Estrogens—osteoporosis	0.000198	0.000454	CcSEcCtD
Orlistat—Vomiting—Zoledronate—osteoporosis	0.000198	0.000453	CcSEcCtD
Orlistat—Feeling abnormal—Estradiol—osteoporosis	0.000198	0.000453	CcSEcCtD
Orlistat—Rash—Zoledronate—osteoporosis	0.000196	0.00045	CcSEcCtD
Orlistat—Gastrointestinal pain—Estradiol—osteoporosis	0.000196	0.000449	CcSEcCtD
Orlistat—Dermatitis—Zoledronate—osteoporosis	0.000196	0.000449	CcSEcCtD
Orlistat—Headache—Zoledronate—osteoporosis	0.000195	0.000447	CcSEcCtD
Orlistat—Vomiting—Conjugated Estrogens—osteoporosis	0.000191	0.000437	CcSEcCtD
Orlistat—Urticaria—Estradiol—osteoporosis	0.000191	0.000437	CcSEcCtD
Orlistat—Abdominal pain—Estradiol—osteoporosis	0.00019	0.000434	CcSEcCtD
Orlistat—Body temperature increased—Estradiol—osteoporosis	0.00019	0.000434	CcSEcCtD
Orlistat—Rash—Conjugated Estrogens—osteoporosis	0.000189	0.000433	CcSEcCtD
Orlistat—Dermatitis—Conjugated Estrogens—osteoporosis	0.000189	0.000433	CcSEcCtD
Orlistat—Headache—Conjugated Estrogens—osteoporosis	0.000188	0.00043	CcSEcCtD
Orlistat—Nausea—Zoledronate—osteoporosis	0.000185	0.000424	CcSEcCtD
Orlistat—Nausea—Conjugated Estrogens—osteoporosis	0.000178	0.000408	CcSEcCtD
Orlistat—Hypersensitivity—Estradiol—osteoporosis	0.000177	0.000405	CcSEcCtD
Orlistat—Asthenia—Estradiol—osteoporosis	0.000172	0.000394	CcSEcCtD
Orlistat—Pruritus—Estradiol—osteoporosis	0.00017	0.000389	CcSEcCtD
Orlistat—Diarrhoea—Estradiol—osteoporosis	0.000164	0.000376	CcSEcCtD
Orlistat—Dizziness—Estradiol—osteoporosis	0.000159	0.000363	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—POMC—osteoporosis	0.000153	0.000434	CbGpPWpGaD
Orlistat—FASN—Metabolism—CYP27A1—osteoporosis	0.000153	0.000433	CbGpPWpGaD
Orlistat—FASN—Disease—GAPDH—osteoporosis	0.000153	0.000432	CbGpPWpGaD
Orlistat—Vomiting—Estradiol—osteoporosis	0.000153	0.000349	CcSEcCtD
Orlistat—Rash—Estradiol—osteoporosis	0.000151	0.000346	CcSEcCtD
Orlistat—Dermatitis—Estradiol—osteoporosis	0.000151	0.000346	CcSEcCtD
Orlistat—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000151	0.000428	CbGpPWpGaD
Orlistat—Headache—Estradiol—osteoporosis	0.00015	0.000344	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—PTHLH—osteoporosis	0.00015	0.000424	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTH—osteoporosis	0.00015	0.000424	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—BMP2—osteoporosis	0.00015	0.000424	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—BMP2—osteoporosis	0.00015	0.000424	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTHLH—osteoporosis	0.00015	0.000424	CbGpPWpGaD
Orlistat—FASN—Metabolism—ACP5—osteoporosis	0.000149	0.000422	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000148	0.000418	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RAP1A—osteoporosis	0.000147	0.000416	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	0.000147	0.000416	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—FGB—osteoporosis	0.000147	0.000415	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—FGB—osteoporosis	0.000147	0.000415	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CALCR—osteoporosis	0.000146	0.000414	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTH1R—osteoporosis	0.000146	0.000414	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CNR2—osteoporosis	0.000146	0.000413	CbGpPWpGaD
Orlistat—FASN—Disease—NFATC1—osteoporosis	0.000145	0.00041	CbGpPWpGaD
Orlistat—FASN—Disease—DKK1—osteoporosis	0.000144	0.000407	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NFATC1—osteoporosis	0.000144	0.000406	CbGpPWpGaD
Orlistat—Nausea—Estradiol—osteoporosis	0.000143	0.000326	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—DKK1—osteoporosis	0.000142	0.000403	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—ENO1—osteoporosis	0.000142	0.000402	CbGpPWpGaD
Orlistat—PNLIP—Disease—KL—osteoporosis	0.000142	0.000401	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PSMA2—osteoporosis	0.000141	0.0004	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PSMA5—osteoporosis	0.000141	0.0004	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PSMA5—osteoporosis	0.000141	0.0004	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PSMA2—osteoporosis	0.000141	0.0004	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PSMA2—osteoporosis	0.00014	0.000397	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PSMA5—osteoporosis	0.00014	0.000397	CbGpPWpGaD
Orlistat—FASN—Disease—WNT1—osteoporosis	0.000139	0.000392	CbGpPWpGaD
Orlistat—FASN—Metabolism—TPI1—osteoporosis	0.000139	0.000392	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—WNT1—osteoporosis	0.000137	0.000388	CbGpPWpGaD
Orlistat—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000136	0.000384	CbGpPWpGaD
Orlistat—FASN—Disease—FGA—osteoporosis	0.000135	0.000381	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—FGA—osteoporosis	0.000133	0.000378	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CALCA—osteoporosis	0.000132	0.000373	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CALCA—osteoporosis	0.000132	0.000373	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—RAP1A—osteoporosis	0.000132	0.000373	CbGpPWpGaD
Orlistat—FASN—Metabolism—P4HB—osteoporosis	0.00013	0.000368	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—POMC—osteoporosis	0.000129	0.000364	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—POMC—osteoporosis	0.000129	0.000364	CbGpPWpGaD
Orlistat—FASN—Metabolism—GAPDH—osteoporosis	0.000128	0.000362	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000125	0.000355	CbGpPWpGaD
Orlistat—FASN—Metabolism—RAP1A—osteoporosis	0.000125	0.000352	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTHLH—osteoporosis	0.000124	0.000351	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—BMP2—osteoporosis	0.000124	0.000351	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	0.000124	0.000351	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—FGB—osteoporosis	0.000121	0.000343	CbGpPWpGaD
Orlistat—FASN—Disease—ENO1—osteoporosis	0.00012	0.00034	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KL—osteoporosis	0.00012	0.000339	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KL—osteoporosis	0.00012	0.000339	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—FGA—osteoporosis	0.00012	0.000338	CbGpPWpGaD
Orlistat—FASN—Disease—PSMA2—osteoporosis	0.000118	0.000335	CbGpPWpGaD
Orlistat—FASN—Disease—PSMA5—osteoporosis	0.000118	0.000335	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TGFB1—osteoporosis	0.000117	0.000332	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TGFB1—osteoporosis	0.000117	0.000332	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PSMA2—osteoporosis	0.000117	0.000332	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PSMA5—osteoporosis	0.000117	0.000332	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—POMC—osteoporosis	0.000117	0.00033	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—POMC—osteoporosis	0.000117	0.00033	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MGLL—osteoporosis	0.000116	0.000329	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PKM—osteoporosis	0.000114	0.000324	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—FDPS—osteoporosis	0.000114	0.000324	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL6R—osteoporosis	0.000114	0.000322	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL6R—osteoporosis	0.000114	0.000322	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—CYP19A1—osteoporosis	0.000114	0.000322	CbGpPWpGaD
Orlistat—PNLIP—Disease—ADCY5—osteoporosis	0.000111	0.000314	CbGpPWpGaD
Orlistat—FASN—Disease—CALCA—osteoporosis	0.00011	0.000312	CbGpPWpGaD
Orlistat—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.00011	0.000311	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CALCA—osteoporosis	0.000109	0.000309	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—FGB—osteoporosis	0.000109	0.000308	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—POMC—osteoporosis	0.000109	0.000307	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GPD2—osteoporosis	0.000108	0.000307	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PGLS—osteoporosis	0.000108	0.000307	CbGpPWpGaD
Orlistat—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000108	0.000307	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	0.000107	0.000304	CbGpPWpGaD
Orlistat—PNLIP—Disease—MTHFR—osteoporosis	0.000102	0.000289	CbGpPWpGaD
Orlistat—FASN—Metabolism—ENO1—osteoporosis	0.000101	0.000285	CbGpPWpGaD
Orlistat—FASN—Disease—KL—osteoporosis	0.0001	0.000283	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ATIC—osteoporosis	9.92e-05	0.000281	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PNP—osteoporosis	9.92e-05	0.000281	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KL—osteoporosis	9.92e-05	0.000281	CbGpPWpGaD
Orlistat—FASN—Metabolism—PSMA2—osteoporosis	9.92e-05	0.000281	CbGpPWpGaD
Orlistat—FASN—Metabolism—PSMA5—osteoporosis	9.92e-05	0.000281	CbGpPWpGaD
Orlistat—PNLIP—Disease—IRS2—osteoporosis	9.71e-05	0.000275	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SOST—osteoporosis	9.57e-05	0.000271	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IGF1—osteoporosis	9.55e-05	0.00027	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ADCY5—osteoporosis	9.38e-05	0.000265	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ADCY5—osteoporosis	9.38e-05	0.000265	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—ADCY5—osteoporosis	9.29e-05	0.000263	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—GPX1—osteoporosis	9.26e-05	0.000262	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SPP1—osteoporosis	9.07e-05	0.000257	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SPP1—osteoporosis	9.07e-05	0.000257	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—MYC—osteoporosis	9.05e-05	0.000256	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	9e-05	0.000255	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	8.9e-05	0.000252	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	8.88e-05	0.000251	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTH1R—osteoporosis	8.65e-05	0.000245	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CALCR—osteoporosis	8.65e-05	0.000245	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—MTHFR—osteoporosis	8.55e-05	0.000242	CbGpPWpGaD
Orlistat—PNLIP—Disease—IRS1—osteoporosis	8.47e-05	0.00024	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—OXCT1—osteoporosis	8.44e-05	0.000239	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CA2—osteoporosis	8.44e-05	0.000239	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MGLL—osteoporosis	8.22e-05	0.000233	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IRS2—osteoporosis	8.2e-05	0.000232	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IRS2—osteoporosis	8.2e-05	0.000232	CbGpPWpGaD
Orlistat—FASN—Metabolism—CYP19A1—osteoporosis	8.05e-05	0.000228	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—LEP—osteoporosis	8.03e-05	0.000227	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—LEP—osteoporosis	8.03e-05	0.000227	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6R—osteoporosis	7.96e-05	0.000225	CbGpPWpGaD
Orlistat—FASN—Disease—ADCY5—osteoporosis	7.85e-05	0.000222	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ADCY5—osteoporosis	7.77e-05	0.00022	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	7.75e-05	0.000219	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTH—osteoporosis	7.7e-05	0.000218	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ESR1—osteoporosis	7.67e-05	0.000217	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ESR1—osteoporosis	7.67e-05	0.000217	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SPP1—osteoporosis	7.52e-05	0.000213	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CNR2—osteoporosis	7.5e-05	0.000212	CbGpPWpGaD
Orlistat—FASN—Disease—MTHFR—osteoporosis	7.22e-05	0.000204	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IRS1—osteoporosis	7.16e-05	0.000203	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IRS1—osteoporosis	7.16e-05	0.000203	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—WNT1—osteoporosis	7.05e-05	0.000199	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—IDH2—osteoporosis	6.99e-05	0.000198	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—POMC—osteoporosis	6.9e-05	0.000195	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—POMC—osteoporosis	6.9e-05	0.000195	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MGLL—osteoporosis	6.88e-05	0.000194	CbGpPWpGaD
Orlistat—FASN—Disease—IRS2—osteoporosis	6.87e-05	0.000194	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—POMC—osteoporosis	6.83e-05	0.000193	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IRS2—osteoporosis	6.8e-05	0.000192	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6R—osteoporosis	6.73e-05	0.00019	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6R—osteoporosis	6.73e-05	0.00019	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LRP5—osteoporosis	6.71e-05	0.00019	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—LEP—osteoporosis	6.65e-05	0.000188	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IGF1—osteoporosis	6.63e-05	0.000188	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IGF1—osteoporosis	6.63e-05	0.000188	CbGpPWpGaD
Orlistat—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	6.6e-05	0.000187	CbGpPWpGaD
Orlistat—FASN—Metabolism—ADCY5—osteoporosis	6.57e-05	0.000186	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP27A1—osteoporosis	6.57e-05	0.000186	CbGpPWpGaD
Orlistat—FASN—Metabolism—GPX1—osteoporosis	6.55e-05	0.000185	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	6.45e-05	0.000182	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	6.43e-05	0.000182	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LRP6—osteoporosis	6.42e-05	0.000182	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ACP5—osteoporosis	6.39e-05	0.000181	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTHLH—osteoporosis	6.38e-05	0.00018	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ESR1—osteoporosis	6.35e-05	0.00018	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	6.31e-05	0.000179	CbGpPWpGaD
Orlistat—FASN—Metabolism—MTHFR—osteoporosis	6.05e-05	0.000171	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	6.01e-05	0.00017	CbGpPWpGaD
Orlistat—FASN—Disease—IRS1—osteoporosis	6e-05	0.00017	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TPI1—osteoporosis	5.94e-05	0.000168	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IRS1—osteoporosis	5.93e-05	0.000168	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	5.73e-05	0.000162	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—POMC—osteoporosis	5.71e-05	0.000162	CbGpPWpGaD
Orlistat—FASN—Disease—IL6R—osteoporosis	5.63e-05	0.000159	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CALCA—osteoporosis	5.61e-05	0.000159	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—P4HB—osteoporosis	5.59e-05	0.000158	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6R—osteoporosis	5.57e-05	0.000158	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IGF1—osteoporosis	5.5e-05	0.000156	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GAPDH—osteoporosis	5.49e-05	0.000155	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TLN1—osteoporosis	5.42e-05	0.000153	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	5.35e-05	0.000151	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—RAP1A—osteoporosis	5.34e-05	0.000151	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL6—osteoporosis	5.07e-05	0.000144	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL6—osteoporosis	5.07e-05	0.000144	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IGF1—osteoporosis	4.92e-05	0.000139	CbGpPWpGaD
Orlistat—FASN—Metabolism—POMC—osteoporosis	4.84e-05	0.000137	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	4.73e-05	0.000134	CbGpPWpGaD
Orlistat—PNLIP—Disease—MYC—osteoporosis	4.72e-05	0.000133	CbGpPWpGaD
Orlistat—PNLIP—Disease—TGFB1—osteoporosis	4.71e-05	0.000133	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—P4HB—osteoporosis	4.67e-05	0.000132	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	4.66e-05	0.000132	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.66e-05	0.000132	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTH—osteoporosis	4.55e-05	0.000129	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RAP1A—osteoporosis	4.47e-05	0.000126	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CNR2—osteoporosis	4.43e-05	0.000125	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NFATC1—osteoporosis	4.36e-05	0.000123	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—DKK1—osteoporosis	4.32e-05	0.000122	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ENO1—osteoporosis	4.32e-05	0.000122	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PSMA2—osteoporosis	4.26e-05	0.00012	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PSMA5—osteoporosis	4.26e-05	0.00012	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—WNT1—osteoporosis	4.17e-05	0.000118	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGA—osteoporosis	4.05e-05	0.000115	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—ADCY5—osteoporosis	3.99e-05	0.000113	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MYC—osteoporosis	3.99e-05	0.000113	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MYC—osteoporosis	3.99e-05	0.000113	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TGFB1—osteoporosis	3.98e-05	0.000113	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TGFB1—osteoporosis	3.98e-05	0.000113	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTHLH—osteoporosis	3.77e-05	0.000107	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BMP2—osteoporosis	3.77e-05	0.000107	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGB—osteoporosis	3.69e-05	0.000104	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PSMA2—osteoporosis	3.56e-05	0.000101	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PSMA5—osteoporosis	3.56e-05	0.000101	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—osteoporosis	3.55e-05	0.0001	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP19A1—osteoporosis	3.45e-05	9.77e-05	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—osteoporosis	3.34e-05	9.44e-05	CbGpPWpGaD
Orlistat—FASN—Disease—TGFB1—osteoporosis	3.33e-05	9.42e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CALCA—osteoporosis	3.32e-05	9.38e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—osteoporosis	3.3e-05	9.35e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TGFB1—osteoporosis	3.3e-05	9.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KL—osteoporosis	3.01e-05	8.52e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—osteoporosis	3e-05	8.48e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—osteoporosis	3e-05	8.48e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TGFB1—osteoporosis	2.95e-05	8.35e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—POMC—osteoporosis	2.94e-05	8.31e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6R—osteoporosis	2.87e-05	8.11e-05	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—POMC—osteoporosis	2.84e-05	8.04e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ADCY5—osteoporosis	2.82e-05	7.98e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GPX1—osteoporosis	2.81e-05	7.95e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PKM—osteoporosis	2.68e-05	7.58e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—FDPS—osteoporosis	2.68e-05	7.58e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MTHFR—osteoporosis	2.59e-05	7.34e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPD2—osteoporosis	2.54e-05	7.19e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PGLS—osteoporosis	2.54e-05	7.19e-05	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—osteoporosis	2.51e-05	7.1e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—osteoporosis	2.48e-05	7.03e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADCY5—osteoporosis	2.36e-05	6.67e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ATIC—osteoporosis	2.32e-05	6.57e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PNP—osteoporosis	2.32e-05	6.57e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SPP1—osteoporosis	2.28e-05	6.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—POMC—osteoporosis	2.08e-05	5.87e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IRS2—osteoporosis	2.06e-05	5.84e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LEP—osteoporosis	2.02e-05	5.71e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CA2—osteoporosis	1.98e-05	5.59e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—OXCT1—osteoporosis	1.98e-05	5.59e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ESR1—osteoporosis	1.93e-05	5.46e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MGLL—osteoporosis	1.93e-05	5.45e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IRS1—osteoporosis	1.8e-05	5.1e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—POMC—osteoporosis	1.74e-05	4.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6R—osteoporosis	1.69e-05	4.79e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1—osteoporosis	1.67e-05	4.72e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—IDH2—osteoporosis	1.64e-05	4.63e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.54e-05	4.35e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ACP5—osteoporosis	1.5e-05	4.24e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TPI1—osteoporosis	1.39e-05	3.94e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—P4HB—osteoporosis	1.31e-05	3.7e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GAPDH—osteoporosis	1.28e-05	3.63e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—osteoporosis	1.28e-05	3.61e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—RAP1A—osteoporosis	1.25e-05	3.54e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ENO1—osteoporosis	1.01e-05	2.86e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—osteoporosis	1e-05	2.84e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFB1—osteoporosis	1e-05	2.83e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PSMA2—osteoporosis	9.97e-06	2.82e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PSMA5—osteoporosis	9.97e-06	2.82e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP19A1—osteoporosis	8.09e-06	2.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—osteoporosis	7.54e-06	2.13e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ADCY5—osteoporosis	6.61e-06	1.87e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPX1—osteoporosis	6.58e-06	1.86e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTHFR—osteoporosis	6.08e-06	1.72e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—POMC—osteoporosis	4.86e-06	1.37e-05	CbGpPWpGaD
